Alaunos Therapeutics Stock Return On Asset
| TCRT Stock | USD 1.09 0.04 3.81% |
Alaunos Therapeutics fundamentals help investors to digest information that contributes to Alaunos Therapeutics' financial success or failures. It also enables traders to predict the movement of Alaunos Stock. The fundamental analysis module provides a way to measure Alaunos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alaunos Therapeutics stock.
Return On Assets is likely to drop to -4.47 in 2024. Alaunos | Return On Asset |
Alaunos Therapeutics Company Return On Asset Analysis
Alaunos Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Alaunos Therapeutics Return On Asset | -0.49 |
Most of Alaunos Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alaunos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alaunos Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Alaunos Therapeutics is extremely important. It helps to project a fair market value of Alaunos Stock properly, considering its historical fundamentals such as Return On Asset. Since Alaunos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alaunos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alaunos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Alaunos Total Assets
Total Assets |
|
Based on the latest financial disclosure, Alaunos Therapeutics has a Return On Asset of -0.4866. This is 94.44% lower than that of the Biotechnology sector and 97.94% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Alaunos Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alaunos Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alaunos Therapeutics could also be used in its relative valuation, which is a method of valuing Alaunos Therapeutics by comparing valuation metrics of similar companies.Alaunos Therapeutics is currently under evaluation in return on asset category among related companies.
Alaunos Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Alaunos Therapeutics from analyzing Alaunos Therapeutics' financial statements. These drivers represent accounts that assess Alaunos Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Alaunos Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 792.7M | 528.3M | 233.7M | 141.0M | 17.0M | 16.1M | |
| Enterprise Value | 715.3M | 418.0M | 187.0M | 121.4M | 10.9M | 10.3M |
Alaunos Fundamentals
| Return On Equity | -1.57 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | 12.99 M | ||||
| Shares Outstanding | 16.01 M | ||||
| Shares Owned By Insiders | 14.29 % | ||||
| Shares Owned By Institutions | 14.61 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Book | 4.09 X | ||||
| Price To Sales | 5,156 X | ||||
| Revenue | 5 K | ||||
| Gross Profit | (19.6 M) | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (35.14 M) | ||||
| Cash And Equivalents | 60.01 M | ||||
| Cash Per Share | 0.28 X | ||||
| Total Debt | 19.51 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 2.29 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (30.14 M) | ||||
| Short Ratio | 28.42 X | ||||
| Earnings Per Share | (32.48) X | ||||
| Target Price | 1.75 | ||||
| Beta | -0.26 | ||||
| Market Capitalization | 17.45 M | ||||
| Total Asset | 8.26 M | ||||
| Retained Earnings | (915.77 M) | ||||
| Working Capital | 6.3 M | ||||
| Net Asset | 8.26 M |
About Alaunos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alaunos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alaunos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alaunos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alaunos Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alaunos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alaunos Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Alaunos Stock
| 0.85 | EQ | Equillium | PairCorr |
Moving against Alaunos Stock
| 0.53 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Alaunos Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alaunos Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alaunos Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alaunos Therapeutics to buy it.
The correlation of Alaunos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alaunos Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alaunos Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alaunos Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alaunos Therapeutics Piotroski F Score and Alaunos Therapeutics Altman Z Score analysis. For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Alaunos Stock analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Alaunos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (32.48) | Quarterly Revenue Growth (0.91) | Return On Assets (0.49) | Return On Equity (1.57) |
The market value of Alaunos Therapeutics is measured differently than its book value, which is the value of Alaunos that is recorded on the company's balance sheet. Investors also form their own opinion of Alaunos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alaunos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alaunos Therapeutics' market value can be influenced by many factors that don't directly affect Alaunos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alaunos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.